Application effect of self-blood acupoint injection in the treatment of bronchial asthma
YANG Yu-zhen HUANG Cheng-zhi ZHOU Juan CHEN Bing LU Hai-ling
Room of Clinical Pharmacology,Department of Pharmacy,Zhanjiang First Hospital of Traditional Chinese Medicine,Guangdong Province,Zhanjiang 524043,China
Abstract:Objective To investigate the effect of self-blood point injection in the treatment of bronchial asthma(BA).Methods From May 2016 to May 2018,76 patients with BA admitted in our hospital were selected and divided into the observation group and the control group according to random number table method,38 cases in each group.The control group was treated with Beclomethasone Propionate Aerosol inhalation and Doxofylline intravenous drip.On the basis of the control group,the patients in the observation group were treated with self-blood injection at acupoint.The clinical efficacy,pulmonary function index,serum IgE and eosinophil count were compared between the two groups before and after treatment,and the recurrence of asthma in the two groups was compared after half a year follow-up.Results The total effective rate of treatment in the observation group was 92.11%,which was higher than that in the control group (73.68%)(P<0.05).Before treatment,there was no significant difference in forced vital capacity(FVC),forced expiratory volume (FEV1)level,serum IgE and eosinophil count between the two groups (P>0.05).After treatment,the level of FVC,FEV1in the observation group was higher than that in the control group,and the levels of serum IgE and eosinophil were significantly lower than those of the control group (P<0.05).The recurrence rate in the observation group was 7.89%,which was lower than that in the control group(23.68%)(P<0.05).There was no statistical significance in the incidence of adverse reactions between the two groups(P>0.05).Conclusion Doxotheophylline combined with self-blood acupoint injection can effectively improve the clinical efficacy,reduce the airway stress response,improve lung function,reduce the recurrence of asthma,and is safe and worthy of clinical promotion.